Cannabis Report
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: Drugdoctor, kkpennies, florida investor, NewTrader2017
Search This Board: 
Last Post: 6/19/2018 3:32:05 PM - Followers: 168 - Board type: Free - Posts Today: 10
* shareholders, please consider purchasing product(s)



Innovus Pharma Launches FlutiCare™ OTC Nasal Spray Allergy Relief in the U.S. Press Release |11/14/2017

Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter (“OTC”) medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has officially launched FlutiCare™ OTC in the U.S. FlutiCare™ contains the most prescribed nasal steroid active pharmaceutical ingredient (“API”) and form for nasal allergy relief over the last 7 years. The Company is launching FlutiCare™ in over 10,000 independent pharmacies, direct and through Amerisource Bergen and McKesson, via its Beyond Human® extensive print media platform and through its extensive online channels and distributors, including its own website, Amazon, and Walmart online stores. As a second phase of its launch, Innovus Pharma will launch FlutiCare™ to large retail stores.

FlutiCare™ will be available OTC with the same prescription strength and same delivery method as Flonase®* and ClariSpray®*. The Company currently believes that FlutiCare™ will be the most affordable fluticasone propionate nasal spray on the market and is now available in one dose, a 30 Day (120 Sprays) treatment and is the only one providing an monthly autoship plan.

“We are very excited to launch FlutiCare™ OTC and provide all patients with allergy relief,” stated Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “FlutiCare™ traces its roots as the most prescribed Rx 24-hour nasal allergy spray API and form in the U.S. over the past 7 years by a factor of over 10 to 1,” he continued.

FlutiCare™ was approved by the U.S. Food and Drug Administration (“FDA”) for OTC availability through Innovus Pharma’s partner’s approved abbreviated new drug application (“ANDA”) No. 207957. FlutiCare™ allergy relief joins the growing Innovus Pharma product family, offering a burgeoning portfolio of non-prescription medicine and consumer care supplements to consumers.

FlutiCare™ becomes the Company’s second available allergy relief product along with AllerVarx™, a patented dietary supplement formulated to provide relief during the allergy season, already on the market.

In addition, the Company, pending FDA’s guidance, plans to move forward with a fluticasone kit for nasal allergy containing FlutiCare™ and our upcoming saline nasal spray NasaVa™.

About FlutiCare™

FlutiCare™ is a nasal spray, which provides 50 micrograms of fluticasone propionate (“USP”) per spray, a nasal corticosteroid that provides 24-hour temporary relief of seasonal and perennial nasal allergy symptoms. FlutiCare™ can be used to relieve both indoor and outdoor nasal allergy symptoms caused by pollen, dust, animal dander, and other indoor and outdoor allergens. Nasal allergy symptoms include, nasal congestion, runny nose, sneezing, itchy nose, etc.

FlutiCare™ contains the nasal steroid API that is physician recommended and consumer preferred

  • #1 form used by patients;
    #1 nasal steroid active prescribed by physicians;
    Familiar to patients, comfort of a known & trusted medicine;
    Engrained in patients’ allergy management; and
    Effective and safe.





Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)


Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer:

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

Who are the major players at Innovus Pharma?


Share Structure:

  Dr. Damaj owns $23.7M shares.  Novalere owns 25.6M.  One person and One Entity own ~ 32.8% of the outstanding shares. 

Profitability expected exiting Q4 2017 !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 


Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call

Corporate Presentation November 2016 (8-K  11/1/2016)

Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)

Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

Major 2016 Accomplishments:



Where can INNV products be seen?


Existing Product Lines @ Innovus Pharma:

Newest Product:


PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. 

The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals.


Are you looking to boost your brain health?r

** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company

Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INNV News: Innovus Pharma Announces the Launch of its Product AllerVarx in Canada for Allergic Rhinitis 06/06/2018 10:11:43 AM
INNV News: Innovus Pharma Announces the Approval of its Product ProstaGorx in Canada for Benign Prostate Hyperplasia ("BPH") ProstaGorx is 06/04/2018 01:46:23 PM
INNV News: Current Report Filing (8-k) 05/30/2018 06:09:35 AM
INNV News: Current Report Filing (8-k) 05/29/2018 03:19:14 PM
INNV News: Innovus Pharma Announces the Launch of its Product Vesele® in Canada 05/17/2018 10:41:13 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#15284  Sticky Note I just refer you to this as well awaitingamove 06/04/18 09:29:29 AM
#15204  Sticky Note Earnings-CALL-REPLAY-and NOTES! Still-Available! To access the replay, dial Drugdoctor 05/28/18 10:21:16 AM
#13583  Sticky Note SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) with kkpennies 02/14/18 08:30:09 PM
#15560   Re: Drugdoctor; Well, due to you being an gi197845 06/19/18 03:32:05 PM
#15559   With some of the TOP Amazon Rankings, I'm Drugdoctor 06/19/18 02:31:13 PM
#15558   Re: Rugdoctor; Ok, it's trading at .11 now. gi197845 06/19/18 02:16:48 PM
#15557   So why don't we say it's trading at Drugdoctor 06/19/18 02:15:52 PM
#15556   Re: Drugdoctor; It's trading at .109 now. I gi197845 06/19/18 02:14:54 PM
#15555   Really, can you provide a link to that? Drugdoctor 06/19/18 01:43:00 PM
#15554   So you're stating the agreement wasn't changed for ShawnP123 06/19/18 10:55:42 AM
#15553   Re: retired early; But for now, it's @ .10.... gi197845 06/19/18 10:17:37 AM
#15552   This one will rock and roll into buck retired early 06/19/18 10:15:39 AM
#15551   You bet... these rankings are EXCEPTIONAL! Drugdoctor 06/19/18 12:51:11 AM
#15550   James Comey would. (I don't drink alcohol at gi197845 06/18/18 07:52:29 PM
#15549   great Rankings, I still think the mos impresive florida investor 06/18/18 07:48:17 PM
#15548   Current rankings: jtaylor68 06/18/18 07:07:59 PM
#15547   You must not drink beer in a court room. jtaylor68 06/18/18 06:49:58 PM
#15546   The agreement was fulfilled in its entirety. Novalere jtaylor68 06/18/18 06:41:52 PM
#15545   ShawnP123 and JTaylor68, I'd like to have you gi197845 06/18/18 04:47:23 PM
#15544   Not to be a stickler but: ShawnP123 06/18/18 10:53:47 AM
#15542   They did. They gave away 12.5M shares for ShawnP123 06/18/18 10:30:32 AM
#15541   He is Brilliant pennymonster1 06/18/18 07:45:10 AM
#15540   Re: Drugdoctor; Neither, would rather wait, buy more gi197845 06/17/18 10:25:38 PM
#15539   So would you rather sell and take a Drugdoctor 06/17/18 10:23:47 PM
#15538   Re: Drugdoctor; I can't sell, because I'm down gi197845 06/17/18 10:22:25 PM
#15537   LOL, there you go again... The financials explain Drugdoctor 06/17/18 10:18:37 PM
#15536   Re: Pennymonster1; Is your "friend" and idiot? Was gi197845 06/17/18 10:18:29 PM
#15535   Re: Drugdoctor; Our lack of profitability and high gi197845 06/17/18 10:14:12 PM
#15534   I never said NET PROFITS for 2018, but Drugdoctor 06/17/18 10:11:28 PM
#15533   Friend told me this is going to $30. pennymonster1 06/17/18 04:58:01 PM
#15532   Re: Drugdoctor; gi197845 06/17/18 02:43:30 PM
#15531   Bottom line is all these new products are Drugdoctor 06/17/18 01:40:43 PM
#15530   Re: Drugdoctor; Ya, that's good news for sure. gi197845 06/17/18 12:58:12 PM
#15529   For a new product on Amazon, to be Drugdoctor 06/17/18 12:53:23 PM
#15528   Re: Drugdoctor; Sorry, duh, I quickly skimmed your gi197845 06/17/18 12:51:28 PM
#15527   I gave you the link.. look it up Drugdoctor 06/17/18 12:44:57 PM
#15526   Re: Drugdoctor; I agree, Fluticare having a #38 gi197845 06/17/18 12:18:06 PM
#15525   Showing 38 right now, but that's still F'ng amazing. Drugdoctor 06/17/18 10:58:48 AM
#15524 florida investor 06/16/18 08:06:55 PM
#15523   Re: Batermere; I'm glad to hear that good gi197845 06/16/18 01:37:22 AM
#15522   gi, I took a couple days off to Batermere 06/15/18 09:04:25 PM
#15521   You've never given the board users a logical jtaylor68 06/15/18 02:20:38 PM
#15520   It is over and it didn't help, because jtaylor68 06/15/18 01:39:41 PM
#15519   Re: JTaylore 68; Thank you very much! If gi197845 06/15/18 11:55:12 AM
#15518   I gave you my sell time. I will ShawnP123 06/15/18 10:01:46 AM
#15517   That locking agreement hasn't helped and I believe ShawnP123 06/15/18 10:00:19 AM
#15516   $5M easily. Diabasens, Fluticare and Urivarx will get jtaylor68 06/15/18 07:15:17 AM
#15515   It's time to put your money where your jtaylor68 06/15/18 07:13:21 AM
#15514   Dr. Damaj amended an agreement and got a jtaylor68 06/15/18 07:07:16 AM
#15513   avid businessman? ShawnP123 06/15/18 06:27:19 AM
#15512   We just need a hint of this quarter's florida investor 06/14/18 09:12:21 PM
#15511   Hmmm...A green day? There appears to be some gi197845 06/14/18 08:40:40 PM
#15510   Investing, sometimes reminds me of being either a gi197845 06/14/18 05:21:53 PM